Login to Your Account

Cytos' $40.6M Financing Gives Asthma Drug Breathing Room

By Marie Powers
Staff Writer

Wednesday, March 28, 2012
Switzerland's Cytos Biotechnology Ltd. stepped away from the ledge of a financial precipice last week and rescued its lead immunodrug candidate CYT003-QbG10 by forging agreements with a syndicate of international investors to raise up to CHF37 million (US$40.6 million) in equity and debt.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription